Scope Fluidics SA (SCP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scope Fluidics SA (SCP) has a cash flow conversion efficiency ratio of -0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.75 Million ≈ $-3.23 Million USD) by net assets (zł115.43 Million ≈ $31.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scope Fluidics SA - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Scope Fluidics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Scope Fluidics SA balance sheet liabilities for a breakdown of total debt and financial obligations.
Scope Fluidics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scope Fluidics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tethys Petroleum Ltd
V:TPL
|
0.069x |
|
CVC Income & Growth Limited
LSE:CVCE
|
0.023x |
|
BTCS Inc
NASDAQ:BTCS
|
-0.011x |
|
Ayes Celik Hasir ve Cit Sanayi AS
IS:AYES
|
-0.018x |
|
Piscines Desjoyaux SA
PA:ALPDX
|
0.136x |
|
Prime Securities Limited
NSE:PRIMESECU
|
-0.056x |
|
Rapid Micro Biosystems Inc
NASDAQ:RPID
|
-0.071x |
|
09women Co. Ltd.
KQ:366030
|
0.036x |
Annual Cash Flow Conversion Efficiency for Scope Fluidics SA (2015–2024)
The table below shows the annual cash flow conversion efficiency of Scope Fluidics SA from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see SCP company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł146.35 Million ≈ $40.28 Million |
zł-25.10 Million ≈ $-6.91 Million |
-0.172x | +27.15% |
| 2023-12-31 | zł80.93 Million ≈ $22.27 Million |
zł-19.06 Million ≈ $-5.24 Million |
-0.235x | -178.45% |
| 2022-12-31 | zł332.97 Million ≈ $91.64 Million |
zł-28.16 Million ≈ $-7.75 Million |
-0.085x | +94.44% |
| 2021-12-31 | zł14.58 Million ≈ $4.01 Million |
zł-22.19 Million ≈ $-6.11 Million |
-1.522x | -215.52% |
| 2020-12-31 | zł33.09 Million ≈ $9.11 Million |
zł-15.96 Million ≈ $-4.39 Million |
-0.482x | +6.93% |
| 2019-12-31 | zł20.22 Million ≈ $5.56 Million |
zł-10.48 Million ≈ $-2.88 Million |
-0.518x | -23.38% |
| 2018-12-31 | zł12.81 Million ≈ $3.52 Million |
zł-5.38 Million ≈ $-1.48 Million |
-0.420x | -43.76% |
| 2017-12-31 | zł16.88 Million ≈ $4.64 Million |
zł-4.93 Million ≈ $-1.36 Million |
-0.292x | +57.84% |
| 2016-12-31 | zł5.58 Million ≈ $1.53 Million |
zł-3.87 Million ≈ $-1.06 Million |
-0.693x | -966.74% |
| 2015-12-31 | zł6.70 Million ≈ $1.84 Million |
zł535.69K ≈ $147.43K |
0.080x | -- |
About Scope Fluidics SA
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.